Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Arrowhead Pharmaceuticals, Inc.
  6. Summary
    ARWR   US04280A1007

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
Real-time Estimate Cboe BZX  -  03:47:05 2023-06-05 pm EDT
35.31 USD   -2.07%
06/02Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating
MT
06/02Alpha-1 Antitrypsin Deficiency (a1atd) Liver Disease Clinical Trials, Growth, and Key Companies | Companies-Centessa Pharmaceuticals, Dicerna Pharmaceuticals PH Pharmaceuticals
AQ
06/01Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/30/2023 05/31/2023 06/01/2023 06/02/2023 06/05/2023 Date
32.78(c) 34.41(c) 34.67(c) 36.05(c) 35.33 Last
725 241 1 859 325 1 026 447 942 438 447 074 Volume
-2.44% +4.97% +0.76% +3.98% -2.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 282 M - -
Net income 2023 -119 M - -
Net cash position 2023 356 M - -
P/E ratio 2023 -27,9x
Yield 2023 -
Sales 2024 180 M - -
Net income 2024 -266 M - -
Net cash position 2024 297 M - -
P/E ratio 2024 -13,4x
Yield 2024 -
Capitalization 3 854 M 3 854 M -
EV / Sales 2023 12,4x
EV / Sales 2024 19,7x
Nbr of Employees 397
Free-Float 96,6%
More Financials
Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis,... 
Read more
More about the company
Ratings of Arrowhead Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ARROWHEAD PHARMACEUTICALS, INC.
06/02Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Mainta..
MT
06/02Alpha-1 Antitrypsin Deficiency (a1atd) Liver Disease Clinical Trials, Growth, and Key C..
AQ
06/01Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
CI
06/01Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
BU
05/23Arrowhead Pharmaceuticals Says Interim Results From ARO-ANG3 Phase 2 Trial Showed Reduc..
MT
05/23Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with Ho..
BU
05/16Arrowhead Pharmaceuticals Completes Enrollment of Late-Stage Clinical Trial of Familial..
MT
05/16Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evalu..
BU
05/15Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
BU
05/15North American Morning Briefing: Hopes Build for -3-
DJ
05/12SVB Leerink Downgrades Arrowhead Pharmaceuticals to Market Perform From Outperform, Pri..
MT
05/08Insider Sell: Arrowhead Pharmaceuticals
MT
05/03Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $73 From $65, Keeps Bu..
MT
05/03Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $40 From $37, Mainta..
MT
05/03Arrowhead Pharmaceuticals Fiscal Q2 Earnings Rise, Revenue Declines
MT
More news
News in other languages on ARROWHEAD PHARMACEUTICALS, INC.
05/16Arrowhead Pharmaceuticals achève le recrutement d'un essai clinique de phase avancée su..
05/08Vente d'initié : Arrowhead Pharmaceuticals
05/03Les bénéfices d'Arrowhead Pharmaceuticals pour le deuxième trimestre fiscal augmentent,..
05/02Arrowhead Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le ..
04/25Arrowhead Pharmaceuticals déclare que l'étude clinique sur ARO-RAGE ne révèle aucun "év..
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on ARROWHEAD PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Global X Genomics & Biotechnology - USD3.93%2.66%-NC
Global X Genomics & Biotechnology ETF - USD3.92%3.23%NC
ALPS Medical Breakthroughs ETF - USD2.13%1.94%United_States
L&G Healthcare Breakthrough - Acc - USD1.63%2.72%-World
Robo Global Healthcare Technology and Innov...1.57%2.96%World
More ETFs positioned on ARROWHEAD PHARMACEUTICALS, INC.
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 36,05 $
Average target price 62,57 $
Spread / Average Target 73,6%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Peter Carignan Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-11.12%3 854
VERTEX PHARMACEUTICALS INCORPORATED15.58%85 966
REGENERON PHARMACEUTICALS, INC.2.56%79 256
WUXI APPTEC CO., LTD.-16.25%28 067
BIONTECH SE-28.02%26 058
GENMAB A/S-7.45%25 588
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer